drugset

drugset / Trial / NCT00312052

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052 ↗

Phase 2 Completed 720 enrolled Eisai Inc.

RandomizedSingle-groupDouble-blindTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of E5555 in subjects with coronary artery disease.

Timeline

Start: 2007-09
Primary completion: 2008-03
Completion: 2009-08

Publications

Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL; LANCELOT-CAD Investigators. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation. 2011 May 3;123(17):1854-63. doi: 10.1161/CIRCULATIONAHA.110.001404. Epub 2011 Apr 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atopaxar	Small molecule	50 mg	Oral
Subject	Atopaxar	Small molecule	100 mg	Oral
Subject	Atopaxar	Small molecule	200 mg	Oral

Indications